This application seeks to renew the Alzheimer's Disease Research Center (ADRC) at the University of California, Irvine (UCI). Our overall objectives are to elucidate the factors that trigger the onset of AD and its conversion from the prodromal state of MCI, and to define the clinical and pathological features of AD. Our ultimate goal is to identify means to prevent, mitigate and eradicate this disorder. Towards this end, the UCI ADRC proposes four Cores and 3 Projects. The Administrative Core, directed by Dr. Carl Cotman and co- directed by Dr. Frank LaFerIa, will manage, guide and support the ADRC. The Clinical Core (Core 6), directed by Dr. Claudia Kawas, follows the standard cohort (controls, MCI and AD) and two unique human cohorts: (1) Down syndrome subjects, which represents the single largest cause of early-onset AD, and (2) individuals over 90 years, a particularly high incidence dementia group well-represented in the area for inclusion in an autopsy study. The Data Management and Statistics Core, directed by Dr. Dan Gillen, will manage ADRC data and support the Cores and ADRC investigators in standard and novel data analysis. The Neuropathology and Tissue Resources Core, co-directed by Dr. Ron Kim and David Cribbs, will collect postmortem and distribute brain tissues and body fluids from the clinical cohorts. The Core will also support investigator driven translational research with transgenic animal models, beta-amyloid peptides (AP) and conformation specific antibodies to A?. The Education and Information Transfer Core, directed by Dr. Ruth Mulnard, will assist in subject recruiting and in education and information among ADRC investigators and the community. To support the overall goals of the ADRC and provide leadership in the field, the UCI ADRC proposes three Projects: 1) Neuroimaging of Hippocampal Subfields in Older Adults &MCI (Project Leader: Craig Stark, Ph.D.);(2) Astrocyte-related molecular mechanisms underlying altered neuronal plasticity in Down syndrome (Project Leader: Jorge Busciglio, Ph.D.) and (3) Neural stem cells to treat and model Alzheimer Disease (Project Leader and new investigator: Mathew Blurton-Jones, Ph.D.). These projects and Cores will interact extensively with other ADRC investigators to continue to build an exciting and productive research environment directed at elucidating the triggers, features and ultimately treatments for cognitive decline and development of AD.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
5P50AG016573-13
Application #
8254412
Study Section
Special Emphasis Panel (ZAG1-ZIJ-4 (J2))
Program Officer
Phelps, Creighton H
Project Start
2000-04-15
Project End
2015-03-31
Budget Start
2012-04-01
Budget End
2013-03-31
Support Year
13
Fiscal Year
2012
Total Cost
$1,889,914
Indirect Cost
$629,661
Name
University of California Irvine
Department
Internal Medicine/Medicine
Type
Organized Research Units
DUNS #
046705849
City
Irvine
State
CA
Country
United States
Zip Code
92697
John, Samantha E; Gurnani, Ashita S; Bussell, Cara et al. (2016) The effectiveness and unique contribution of neuropsychological tests and the δ latent phenotype in the differential diagnosis of dementia in the uniform data set. Neuropsychology 30:946-960
Bonham, Luke W; Geier, Ethan G; Fan, Chun C et al. (2016) Age-dependent effects of APOE ε4 in preclinical Alzheimer's disease. Ann Clin Transl Neurol 3:668-77
Paganini-Hill, Annlia; Kawas, Claudia H; Corrada, Maria M (2016) Lifestyle Factors and Dementia in the Oldest-old: The 90+ Study. Alzheimer Dis Assoc Disord 30:21-6
Ting, Simon Kang Seng; Hao, Ying; Chia, Pei Shi et al. (2016) Clinicopathological correlation of psychosis and brain vascular changes in Alzheimer's disease. Sci Rep 6:20858
Tosto, Giuseppe; Monsell, Sarah E; Hawes, Stephen E et al. (2016) Progression of Extrapyramidal Signs in Alzheimer's Disease: Clinical and Neuropathological Correlates. J Alzheimers Dis 49:1085-93
Grill, Joshua D; Zhou, Yan; Elashoff, David et al. (2016) Disclosure of amyloid status is not a barrier to recruitment in preclinical Alzheimer's disease clinical trials. Neurobiol Aging 39:147-53
Chapman, Kimberly R; Bing-Canar, Hanaan; Alosco, Michael L et al. (2016) Mini Mental State Examination and Logical Memory scores for entry into Alzheimer's disease trials. Alzheimers Res Ther 8:9
Fischer, Corinne E; Qian, Winnie; Schweizer, Tom A et al. (2016) Lewy Bodies, Vascular Risk Factors, and Subcortical Arteriosclerotic Leukoencephalopathy, but not Alzheimer Pathology, are Associated with Development of Psychosis in Alzheimer's Disease. J Alzheimers Dis 50:283-95
Leal, Stephanie L; Noche, Jessica A; Murray, Elizabeth A et al. (2016) Positivity effect specific to older adults with subclinical memory impairment. Learn Mem 23:415-21
Karch, Celeste M; Ezerskiy, Lubov A; Bertelsen, Sarah et al. (2016) Alzheimer's Disease Risk Polymorphisms Regulate Gene Expression in the ZCWPW1 and the CELF1 Loci. PLoS One 11:e0148717

Showing the most recent 10 out of 383 publications